CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
June 10, 2021—Labcorp and OmniSeq announced the launch of OmniSeq Insight, a next-generation–sequencing, pan-cancer, solid tumor test that combines genomic and immune profiling, including tumor mutational burden, microsatellite instability, and immune gene expression.
Test results are presented in an easy-to-read report that summarizes all FDA-approved therapies and immunotherapies that match the patient’s tumor profile and identifies clinical trials for which a patient may be eligible, within 200 miles of the patient’s home. The report provides evidence-based recommendations specific to the individual test results through the use of a proprietary database sourced from biologic and scientific literature, including National Comprehensive Cancer Network guidelines.